

30 January 2024

**Cambridge Cognition Holdings Plc**  
("Cambridge Cognition", the "Company" or the "Group")  
**Director/PDMR Share Purchases**

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, was informed on 30 January 2024 that Nick Rodgers, Non-Executive Director of the Company, purchased 20,000 ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of 52.449 pence per share.

Following this transaction, Nick Rodgers holds an interest in 20,000 Ordinary Shares, representing approximately 0.06% of the Company's issued share capital.

Further information on the purchases is contained in the disclosure tables below.

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:**

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Nick Rodgers	
2	Reason for the notification		
a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Cambridge Cognition Holdings Plc	
b)	LEI	213800SZKDIN122EPA96	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary shares of 0.01p each  GB00B8DV9647	
b)	Nature of the transaction	Purchase of Shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		52.449 pence	20,000
d)	Aggregated information  - Aggregated volume  - Price	n/a	
e)	Date of the transaction	30 January 2024	
f)	Place of the transaction	London Stock Exchange	

**For further information, please contact:**

**Cambridge Cognition Holdings Plc**  
Matthew Stork, Chief Executive Officer  
Stephen Symonds, Chief Financial Officer

Tel: 012 2381 0700  
[press@camcog.com](mailto:press@camcog.com)

**Panmure Gordon (UK) Limited (NOMAD and Joint Broker)**  
Freddy Crossley / Emma Earl  
Rupert Dearden

Tel: 020 7886 2500  
(Corporate Finance)  
(Corporate Broking)

**Dowgate Capital Limited (Joint Broker)**  
David Poutney / James Serjeant

Tel: 020 3903 7715

**Hudson Sandler (Financial PR and IR)**  
Dan de Belder / Hattie Dreyfus

Tel: 020 7796 4133  
[cog@hudsonsandler.com](mailto:cog@hudsonsandler.com)

**Notes to Editors**

**About Cambridge Cognition**

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit [www.cambridgecognition.com](http://www.cambridgecognition.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lse.com](mailto:ms@lse.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHWPUBGGUPCGQU